Navigation Links
BioAdaptives Prepares for Next Step

LAS VEGAS, July 14, 2014 /PRNewswire/ -- BioAdaptives, Inc. (OTCBB:BDPT) is pleased to announce Mr. Barry Epling, Chairman has assumed the roles of President and CEO of the Company.  Mr. Epling is the owner of Ferris Holding, Inc., the company that licensed its formulation, intellectual properties, and other technologies to BioAdaptives, Inc. and its financial supporter.

"Mr. Gerald Epling, who has been overseeing BioAdaptives from our early transition as a privately held entity to a public company, has decided to return to the private sector to concentrate on other interests," said Mr. Barry Epling, who went on to say, "We appreciate the dedication of Gerald Epling to the Company and his contributions, he will be missed."

Mr. Barry Epling added, "Due to the success of the human clinical trial on our stem cell activating product and the acceptance in test markets both in the United States and overseas, a stronger involvement under my direct supervision is required. These positive results suggest a number of avenues should be explored to develop a family of products to further the success of the company and offer significant benefits to both humans and animals."

About BioAdaptives, Inc.

BioAdaptives, Inc. is a fully-reporting public company trading on the OTC Bulletin Board under the symbol BDPT. The company is engaged in research and development in science-based nutraceutical products for both human and animal consumption.  The company's focus, in conjunction with Ferris Holding, Inc., is to source high quality, unique raw material worldwide and develop science-based products to improve health and wellness for both humans and animals.  It has also developed a proprietary method that is a non-intrusive bioelectromagnetic device for improving food, beverages, and wellness.


Forward-Looking Statements: This release contains statements that constitute forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. These statements appear in a number of places in this release and include all statements that are not statements of historical fact regarding the intent, belief or current expectations of BioAdaptives, Inc its directors or its officers with respect to, among other things: (i) financing plans; (ii) trends affecting its financial condition or results of operations; (iii) growth strategy and operating strategy. The words "may," "would," "will," "expect," "estimate," "can," "believe," "potential" and similar expressions and variations thereof are intended to identify forward-looking statements. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond BioAdaptives, Inc's ability to control, and actual results may differ materially from those projected in the forward-looking statements as a result of various factors. More information about the potential factors that could affect the business and financial results is and will be included in BioAdaptives, Inc's filings with the Securities and Exchange Commission.

SOURCE BioAdaptives, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Related medicine technology :

1. The Midwest Prepares to Tackle Gnats with an Unlikely Weapon
2. PAZOO Prepares For First Three National Direct Response Campaigns and Distribution of PAZOO Branded Products
3. MDHI Restocks Inventories - Prepares for Additional Retail Promotions With Americas Largest Discount Warehouse Chain
4. Emdeon Ranked First in Electronic Prescribing Interoperability and EHR Vendor Support for CPOE; Prepares for Stage 2 Meaningful Use
5. Narcolepsy Patient Community Prepares to Share Life Impacts, Treatment Perspectives with FDA Regulators
6. Pharmagen Partners with Bagel Boy Equity Group II, LLC and prepares to Launch its Industry Consolidation Strategy
7. SPO Prepares for Growth in 2014
Post Your Comments:
(Date:10/11/2017)... 11, 2017  True Health, a leader in ... effort during National Breast Cancer Awareness month to ... Research recently ... that more than 10 million American women are ... BRCA1 or BRCA2 and have not had testing. These ...
(Date:10/7/2017)... Texas , Oct. 6, 2017   Provista, ... with more than $100 billion in purchasing power, today ... news and information. The Newsroom is the ... and industry trends, infographics, expert bios, news releases, slideshows ... having access to a wealth of resources at their ...
(Date:10/4/2017)... 2017 OBP Medical , a ... devices, today announced regulatory approval from ... Agência Nacional de Vigilância Sanitária (ANVISA)) to market ... retractor with integrated LED light source and smoke ... exposure of a tissue pocket or cavity during ...
Breaking Medicine Technology:
(Date:10/13/2017)... ... October 13, 2017 , ... ... Agile Software Development, has been awarded a contract by the Center for Medicare ... (BPA) aims to accelerate the enterprise use of Agile methodologies in a consistent ...
(Date:10/13/2017)... ... October 13, 2017 , ... “America On The Brink”: the Christian history ... The Brink” is the creation of published author, William Nowers. Captain Nowers and ... WWII veteran, he spent thirty years in the Navy. Following his career as ...
(Date:10/12/2017)... ... October 12, 2017 , ... CitiDent and ... apnea using cutting-edge Oventus O2Vent technology. As many as 18 million Americans ... frequent cessation in breathing. Oral appliances can offer significant relief to about 75 ...
(Date:10/12/2017)... ... 12, 2017 , ... The company has developed a suite ... regulatory authorities worldwide. From Children’s to Adults 50+, every formula has been developed ... , These products are also: Gluten Free, Non-GMO, Vegan, Soy Free, Non-Dairy*, ...
(Date:10/12/2017)... (PRWEB) , ... October 12, 2017 , ... The American ... Excellence to Carol Friedman, PhD, FACMI, during the Opening Session of AMIA’s Annual Symposium ... 8. , In honor of Morris F. Collen, a pioneer in the field of ...
Breaking Medicine News(10 mins):